Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 3Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × tocilizumab × Thoracic × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡